drugset / Trial / NCT05821374
Deucravacitinib in PG
NaSingle-groupOpen-labelTreatment
Summary
The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and effective in treating people with pyoderma gangrenosum (PG).
Timeline
- Start
- 2024-04-29
- Primary completion
- 2024-04-29
- Completion
- 2024-04-29
Outcome
Outcome not reported
Stopped (Business): “Issues with funding and IND holder”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CRAVACITINIB | Small molecule | 6 mg | Oral |